- Home
- UG vs BCAB Comparison
UG vs BCAB Comparison
Compare UG & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UG
- BCAB
- Stock Information
- Founded
- UG 1942
- BCAB 2007
- Country
- UG United States
- BCAB United States
- Employees
- UG N/A
- BCAB N/A
- Industry
- UG Package Goods/Cosmetics
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- UG Consumer Discretionary
- BCAB Health Care
- Exchange
- UG Nasdaq
- BCAB Nasdaq
- Market Cap
- UG 36.4M
- BCAB 40.5M
- IPO Year
- UG N/A
- BCAB 2020
- Fundamental
- Price
- UG $7.23
- BCAB $0.71
- Analyst Decision
- UG
- BCAB Hold
- Analyst Count
- UG 0
- BCAB 3
- Target Price
- UG N/A
- BCAB $1.00
- AVG Volume (30 Days)
- UG 6.4K
- BCAB 1.5M
- Earning Date
- UG 11-11-2025
- BCAB 11-05-2025
- Dividend Yield
- UG 9.59%
- BCAB N/A
- EPS Growth
- UG N/A
- BCAB N/A
- EPS
- UG 0.56
- BCAB N/A
- Revenue
- UG $10,856,174.00
- BCAB $11,000,000.00
- Revenue This Year
- UG N/A
- BCAB N/A
- Revenue Next Year
- UG N/A
- BCAB N/A
- P/E Ratio
- UG $13.12
- BCAB N/A
- Revenue Growth
- UG N/A
- BCAB N/A
- 52 Week Low
- UG $7.25
- BCAB $0.24
- 52 Week High
- UG $14.05
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- UG 42.03
- BCAB 47.73
- Support Level
- UG $7.36
- BCAB $0.67
- Resistance Level
- UG $7.49
- BCAB $0.76
- Average True Range (ATR)
- UG 0.15
- BCAB 0.10
- MACD
- UG -0.00
- BCAB -0.02
- Stochastic Oscillator
- UG 11.16
- BCAB 24.35
About UG United-Guardian Inc.
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.